Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11701544 | 0.89 | P2RX3 (0.34) | ALDH1A1MAPK1SMN1; SMN2CCNA2CDK2 | |
| SCHEMBL14395834 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL16828162 | 0.74 | CCNA2 (0.50) | ALDH1A1CCNA2CDK2CCNA1TLR8 | |
| SCHEMBL5765616 | 0.73 | POLB (0.49) | ALDH1A1MAPK1CDK2PDE4A | |
| SCHEMBL14621844 | 0.73 | P2RX3 (0.37) | P2RX3P2RX2TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL16828222 | 0.72 | CCNA2 (0.48) | ALDH1A1CCNA2CDK2CCNA1TLR8 | |
| SCHEMBL3674088 | 0.72 | PKM (0.37) | SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL5765829 | 0.72 | CYP1A2 (0.39) | ALDH1A1CCNA2CDK2CCNA1 | |
| SCHEMBL13752400 | 0.71 | KMT2A (0.46) | ALDH1A1MAPK1SMN1; SMN2CCNA2CDK2 | |
| SCHEMBL13952887 | 0.71 | CCNA2 (0.40) | CCNA2CDK2CCNA1TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1334972-B1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6833372-B2 | A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups | PFIZER, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1334972-A1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER INC. (US) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110708-A1 | Silicon compounds and their use | SOST, SMAD3, SMAD2 | ALDH1A1 2166/4885MAPK1 2677/4885SMN1; SMN2 330/4885 |
| US-20070111967-A1 | Organosilicon compounds and their use | CYP2B6, UGT1A6, CYP2D6 | ALDH1A1 198/4885MAPK1 4010/4885SMN1; SMN2 3410/4885 |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | GNRHR, LHCGR, FSHR | ALDH1A1 4860/4885MAPK1 2748/4885SMN1; SMN2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.